دورية أكاديمية
Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study
| العنوان: | Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study |
|---|---|
| المؤلفون: | Mitjavila Casanovas, Mercedes, Jimenez Fonseca, Paula, BELLO, PILAR, Pubul Núñez, Virginia, Percovich, Juan Carlos, Garcia-Burillo, Amparo, Hernando Cubero, Jorge |
| المساهمون: | Institut Català de la Salut, Mitjavila M Department of Nuclear Medicine, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. Jimenez-Fonseca P Department of Medical Oncology, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain. Belló P Department of Nuclear Medicine, Hospital Universitario La Fe, Valencia, Spain. Pubul V Department of Nuclear Medicine, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain. Percovich JC Department of Endocrinology and Nutrition, Hospital Universitario Gregorio Marañón, Madrid, Spain. Garcia-Burillo A Servei de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Hernando J Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| المصدر: | Scientia |
| بيانات النشر: | Springer |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Tumors neuroendocrins - Tractament, Radiofàrmacs, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine Tumors, Other subheadings::Other subheadings::/therapy, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Diagnostic Uses of Chemicals::Radiopharmaceuticals, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinos, Otros calificadores::Otros calificadores::/terapia, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos diagnósticos de sustancias químicas::radiofármacos |
| الوصف: | Neuroendocrine tumor; Radionuclide therapy ; Tumor neuroendocrí; Teràpia amb radionúclids ; Tumor neuroendocrino; Terapia con radionúclidos ; Background Peptide receptor radionuclide therapy (PRRT) is one of the most promising therapeutic strategies in neuroendocrine neoplasms (NENs). Nevertheless, its role in certain tumor sites remains unclear. This study sought to elucidate the efficacy and safety of [177Lu]Lu-DOTATATE in NENs with different locations and evaluate the effect of the tumor origin, bearing in mind other prognostic variables. Advanced NENs overexpressing somatostatin receptors (SSTRs) on functional imaging, of any grade or location, treated at 24 centers were enrolled. The protocol consisted of four cycles of 177Lu-DOTATATE 7.4 GBq iv every 8 weeks (NCT04949282). Results The sample comprised 522 subjects with pancreatic (35%), midgut (28%), bronchopulmonary (11%), pheochromocytoma/ paraganglioma (PPGL) (6%), other gastroenteropancreatic (GEP) (11%), and other non-gastroenteropancreatic (NGEP) (9%) NENs. The best RECIST 1.1 responses were complete response, 0.7%; partial response, 33.2%; stable disease, 52.1%; and tumor progression, 14%, with activity conditioned by the tumor subtype, but with benefit in all strata. Median progression-free survival (PFS) was 31.3 months (95% CI, 25.7–not reached [NR]) in midgut, 30.6 months (14.4-NR) in PPGL, 24.3 months (18.0-NR) in other GEP, 20.5 months (11.8-NR) in other NGEP, 19.8 months (16.8–28.1) in pancreatic, and 17.6 months (14.4–33.1) in bronchopulmonary NENs. [177Lu]Lu-DOTATATE exhibited scant severe toxicity. Conclusion This study confirms the efficacy and safety of [177Lu]Lu-DOTATATE in a wide range of SSTR-expressing NENs, regardless of location, with clinical benefit and superimposable survival outcomes between pNENs and other GEP and NGEP tumor subtypes different from midgut NENs. ; The SEPTRALU registry received external funding from Novartis. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1619-7089 |
| العلاقة: | European Journal of Nuclear Medicine and Molecular Imaging;50; https://doi.org/10.1007/s00259-023-06166-8Test; Mitjavila M, Jimenez-Fonseca P, Belló P, Pubul V, Percovich JC, Garcia-Burillo A, et al. Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study. Eur J Nucl Med Mol Imaging. 2023 Jul;50:2486–500.; https://hdl.handle.net/11351/9825Test; 000951227100001 |
| DOI: | 10.1007/s00259-023-06166-8 |
| الإتاحة: | https://doi.org/10.1007/s00259-023-06166-8Test https://hdl.handle.net/11351/9825Test |
| حقوق: | Attribution 4.0 International ; http://creativecommons.org/licenses/by/4.0Test/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.5E4B3353 |
| قاعدة البيانات: | BASE |
| تدمد: | 16197089 |
|---|---|
| DOI: | 10.1007/s00259-023-06166-8 |